Versor Investments LP Raises Stock Position in ICU Medical, Inc. (NASDAQ:ICUI)

Versor Investments LP grew its holdings in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 210.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 7,118 shares of the medical instruments supplier's stock after purchasing an additional 4,822 shares during the period. Versor Investments LP's holdings in ICU Medical were worth $1,297,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Motco bought a new stake in ICU Medical in the 1st quarter valued at about $29,000. Innealta Capital LLC purchased a new position in ICU Medical in the second quarter valued at approximately $32,000. Hexagon Capital Partners LLC lifted its stake in ICU Medical by 162.7% in the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier's stock valued at $36,000 after purchasing an additional 122 shares during the last quarter. Allworth Financial LP lifted its position in shares of ICU Medical by 100.0% during the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier's stock worth $36,000 after acquiring an additional 100 shares in the last quarter. Finally, EntryPoint Capital LLC lifted its position in shares of ICU Medical by 731.5% during the first quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier's stock worth $48,000 after acquiring an additional 395 shares in the last quarter. Institutional investors own 96.10% of the company's stock.

Insider Transactions at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at $16,320,691.72. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CEO Vivek Jain sold 12,000 shares of the company's stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $156.04, for a total value of $1,872,480.00. Following the completion of the transaction, the chief executive officer now owns 104,593 shares in the company, valued at $16,320,691.72. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel Woolson sold 2,502 shares of the company's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $163.22, for a total transaction of $408,376.44. Following the sale, the vice president now directly owns 13,107 shares in the company, valued at $2,139,324.54. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,502 shares of company stock worth $8,445,976 over the last three months. 6.70% of the stock is currently owned by insiders.

ICU Medical Stock Down 0.1 %

Shares of NASDAQ ICUI traded down $0.26 during trading hours on Tuesday, hitting $178.01. The stock had a trading volume of 267,471 shares, compared to its average volume of 273,286. The company has a market capitalization of $4.35 billion, a P/E ratio of -61.05 and a beta of 0.66. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41. The firm's 50-day moving average price is $175.56 and its two-hundred day moving average price is $141.16. ICU Medical, Inc. has a 52 week low of $79.85 and a 52 week high of $188.53.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. KeyCorp raised their price objective on ICU Medical from $147.00 to $198.00 and gave the company an "overweight" rating in a research note on Tuesday, October 15th. Needham & Company LLC restated a "hold" rating on shares of ICU Medical in a report on Thursday, October 10th. StockNews.com upgraded shares of ICU Medical from a "hold" rating to a "buy" rating in a research note on Thursday, September 12th. Jefferies Financial Group began coverage on shares of ICU Medical in a research report on Monday, October 14th. They set a "hold" rating and a $183.00 target price for the company. Finally, Raymond James raised their price target on shares of ICU Medical from $158.00 to $190.00 and gave the company an "outperform" rating in a research report on Thursday, September 12th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, ICU Medical presently has an average rating of "Moderate Buy" and an average target price of $170.25.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.